Perioperative Changes of Serum p53 Antibody Titer is a Predictor for Survival in Patients with Esophageal Squamous Cell Carcinoma
- 247 Downloads
Although the presence of serum p53 antibody (s-p53-Abs) before treatment has been shown to correlate with poor prognosis and lymph node metastasis in esophageal cancer, there has been little information about postoperative s-p53-Abs titer and perioperative changes of s-p53-Abs titers in patients with esophageal carcinoma.
A highly specific enzyme-linked immunosorbent assay was used to analyze s-p53-Abs in 110 patients with esophageal squamous cell carcinoma before and 1 month after surgery. The cutoff level of 1.3 U/ml was used to indicate seropositive patients. Impact of postoperative s-p53-Abs titer and perioperative changes of s-p53-Abs on survival was evaluated.
Forty (36%) of 110 patients were positive for s-p53-Abs before surgery and 35 patients (32%) were positive after surgery. s-p53-Abs titer generally decreased after surgery. Among sero-positive patients, the patients who remained sero-positive after surgery (n = 28) had a worse prognosis than patients who showed sero-conversion (P = 0.02). Among sero-positive patients, the nondecreased titer group showed significantly unfavorable survival (P < 0.01). Multivariate analysis revealed that postoperative s-p53-Abs was an independent risk factor for worse overall survival (adjusted hazard ratio = 3.05; 95% confidence interval = 1.11–8.33; P = 0.03).
Perioperative monitoring of s-p53-Abs titers was useful to identify patients with esophageal cancer with a high risk for tumor recurrence and a poor prognosis. Continuous sero-positive patients and/or nondecreased titer group, even after surgery, showed significantly unfavorable survival.
KeywordsEsophageal Cancer Esophageal Squamous Cell Carcinoma Serum Titer Seropositive Patient Titer Group
- 6.von Brevern MC, Hollstein MC, Cawley HM et al (1996) Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 56:4917–4921Google Scholar
- 7.Collet B, Raoul JL, Berre NL et al (1997) Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus: comparison with p53 alterations and lymph node invasion. Int J Oncol 11:617–621Google Scholar
- 13.Sobin LH, Wittekind CH (eds) (2002) UICC International Union Against Cancer TNM classification of malignant tumors, 6th edn edn. Wiley, New YorkGoogle Scholar